Diflunisal — Discount Pricing

Other medications in Pain & Inflammation

• Dihydroergotamine
• Eletriptan
• Ergotamine
• Etodolac
• Fenoprofen
• Flurbiprofen
• Frovatriptan
• Hydrocodone

About Diflunisal

Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed to manage mild to moderate pain, osteoarthritis, and rheumatoid arthritis. It works by reducing inflammation and pain in the body. For those managing these conditions, prescription costs can add up. TheDrugClub is dedicated to helping members find significant savings on medications like diflunisal, making essential treatments more accessible.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Diflunisal is approved for (FDA label)

Carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: Mild to moderate pain Osteoarthritis Rheumatoid arthritis

Source: Read the full FDA label on DailyMed. Label effective date: August 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Diflunisal (FDA label)

Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS ). Diflunisal tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATION and WARNINGS ). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: 666f89b4-fd81-420a-a390-eb1cd4014f61. SPL document ID: 7616a7e4-96d0-4581-9b77-e9292726282b. Label effective date: August 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Diflunisal (FDA label)

The adverse reactions observed in controlled clinical trials encompass observations in 2,427 patients. Listed below are the adverse reactions reported in the 1,314 of these patients who received treatment in studies of two weeks or longer. Five hundred thirteen patients were treated for at least 24 weeks, 255 patients were treated for at least 48 weeks, and 46 patients were treated for 96 weeks. In general, the adverse reactions listed below were 2 to 14 times less frequent in the 1,113 patients who received short-term treatment for mild to moderate pain. Incidence Greater Than 1% Gastrointestinal The most frequent types of adverse reactions occurring with diflunisal are gastrointestinal: these include nausea*, vomiting, dyspepsia*, gastrointestinal pain*, diarrhea*, constipation, and flatulence.

Source: FDA prescribing information (DailyMed). Set ID: 666f89b4-fd81-420a-a390-eb1cd4014f61. SPL document ID: 7616a7e4-96d0-4581-9b77-e9292726282b. Label effective date: August 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.